' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.
Kalathur, M; Toso, A; Chen, J; Revandkar, A; Danzer-Baltzer, C; Guccini, I; Alajati, A; Sarti, M; Pinton, S; Brambilla, L; Di Mitri, D; Carbone, G; Garcia-Escudero, R; Padova, A; Magnoni, L; Tarditi, A; Maccari, L; Malusa, F; Kalathur, RK; A Pinna, L; Cozza, G; Ruzzene, M; Delaleu, N; Catapano, CV; Frew, IJ; Alimonti, A;
Nat Commun. 2015; 6:7227
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Kalathur Ravi

Abstract

Enhancement of cellular senescence in tumours triggers a stable cell growth arrest and activation of an antitumour immune response that can be exploited for cancer therapy. Currently, there are only a limited number of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells. Here we developed a chemogenomic screening to identify compounds that enhance senescence in PTEN-deficient cells without affecting normal cells. By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target. Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3. CK2 upregulation in Pten null tumours affects the stability of Pml, an essential regulator of senescence. However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumours. Taken together, our screening strategy has identified a novel STAT3-CK2-PML network that can be targeted for pro-senescence therapy for cancer.


Useful keywords (using NLM MeSH Indexing)

Animals

Casein Kinase II/antagonists*

inhibitors*

Casein Kinase II/metabolism

Cell Aging/drug effects*

Drug Evaluation, Preclinical

Female

HCT116 Cells

Humans

Male

Mice, Transgenic

Molecular Targeted Therapy*

Naphthyridines/pharmacology

Naphthyridines/therapeutic use*

Nuclear Proteins/metabolism

PTEN Phosphohydrolase/deficiency*

Promyelocytic Leukemia Protein

Prostatic Neoplasms/drug therapy*

RNA, Small Interfering

STAT3 Transcription Factor/metabolism

Transcription Factors/metabolism

Tumor Suppressor Proteins/metabolism